Low-grade ESS characterized by JAZF1::SUZ12 and related fusions may be susceptible to agents targeting chromatin remodeling or Wnt signaling, complementing established hormonal therapies [65]. This evidence concerns the gene JAZF1 and endometrioid stromal sarcoma.